Table 3.
Clinical characteristics, PLM and ferritin levels in controls and NT1 patients.
| Variable |
Controls N = 38 |
NT1 patients N = 66 |
Model 0 | Model 1 | ||
|---|---|---|---|---|---|---|
| n | % | n | % | P | P | |
| Gender, women | 26 | 68.42 | 22 | 33.33 | 0.0008 | |
| Age, years 1 | 22.50 (12.00; 61.00) | 38.50 (14.00; 81.00) | 0.0009 | |||
| BMI, kg/m2 1 | 20.77 (16.45; 35.19) | 26.12 (18.73; 37.11) | <0.0001 | |||
| ESS score 1 | 15.00 (5.00 ;23.00) | 20.00 (6.00 ;24.00) | 0.001 | |||
| Duration of evolution of NT1, years 1 | – | 10 (1.00; 69.00) | – | |||
| PLM indexes | ||||||
| Index PLMS, /h 1 | 0.17 (0.00; 14.20) | 4.10 (0.00; 161.90) | 0.005 | |||
| Index PLMS ≥15/h | 0 | 0 | 18 | 27.27 | NA | |
| Index PLMS associated with MA, /h 1 | 0.00 (0.00; 3.30) | 1.30 (0.00; 50.70) | 0.02 | |||
| Index of PLMS associated with MA ≥15/h | 0 | 0 | 2 | 3.17 | NA | |
| Index PLM wake, /h 1 | 1.50 (0.00; 62.00) | 11.55 (0.00; 105.60) | 0.56 | |||
| Index PLM wake ≥15/h | 7 | 18.42 | 25 | 39.06 | 0.87 | |
| Ferritin levels | ||||||
| Ser‐Ferr, ng/mL 1 | 51.50 (6.00; 418.00) | 100.00 (12.00; 500.00) | 0.009 | |||
| Ser‐Ferr ≤50 ng/mL | 15 | 50.00 | 12 | 19.05 | 0.003 | |
| Ser‐Ferr ≤75 ng/mL | 18 | 60.00 | 21 | 33.33 | 0.02 | |
| CSF‐Ferr, ng/mL 1 | 4.87 (2.09; 11.98) | 6.64 (3.00; 14.89) | 0.0008 | 0.09 | ||
| CSF‐Ferr, ng/mL 2 | ||||||
| <4.66 | 18 | 47.37 | 15 | 22.73 | 0.008 | 0.26 |
| [4.66–6.89] | 14 | 36.84 | 22 | 33.33 | ||
| ≥6.89 | 6 | 15.79 | 29 | 43.94 | ||
Model 0: crude association. Model 1: adjustment for age, gender, and serum ferritin levels. BMI, body mass index; CSF, cerebrospinal fluid; CSF‐Ferr, CSF ferritin levels; ESS, Epworth sleepiness scale; MA, microarousal; NT1, narcolepsy type 1; PLM, periodic leg movements; PLMS, periodic leg movements during sleep; RLS, restless legs syndrome; Ser‐Ferr, serum ferritin levels; NA, test not applicable.
1
Continuous variables are expressed as median (minimal value; maximal value).
2
Tertiles of the whole sample (n = 104).